MedTrace Logo

Efficacy and Safety of Ainuovirine Treating With AIDS Patients

NCT05420246 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2022-06-15

No results posted yet for this study

Summary

Ainuovirine is the third generation of non nucleoside reverse transcriptase inhibitors(NNRTIs), for the treatment of HIV-1 infected adults. The existing clinical studies show that Ainuovirine is safe and potent, it solves the problem from the first-generation NNRTIs such as Efavirenz with large side effects and the second-generation like Rilpivirine not suitable for high viral load, but there are no relevant data or reports on the efficacy and safety of Ainuovirine in HIV-infected patients in China so far. This project aims to explore the efficacy and safety of ART regimens containing Ainuovirine for HIV-infected patients in real clinical environment, in further to guide clinical application.

Conditions

Interventions

DRUG

Ainuovirine

The regimen including Ainuovirine will be given to HIV-1 infected/AIDS patients.

Sponsors & Collaborators

  • Guangzhou 8th People's Hospital

    lead OTHER

Principal Investigators

  • Ruosu Ying, Doctor · Guangzhou Eighth People's Hospital

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05420246 on ClinicalTrials.gov